Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Weight-Loss drug tested in kidney patients

NCT ID NCT07443059

First seen Mar 10, 2026 · Last updated May 18, 2026 · Updated 8 times

Summary

This early-phase study looks at how a single dose of ZT002 (a potential weight-loss drug) behaves in people with different levels of kidney function. About 40 adults who are overweight or obese will receive one injection, and researchers will measure drug levels and safety. The goal is to understand if kidney problems affect how the drug is processed, not to treat the kidney disease itself.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 250014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital Of Shandong First Medical Unversity

    RECRUITING

    Jinan, Shandong, 250014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Xiamen University

    NOT_YET_RECRUITING

    Xiamen, Fujian, 361003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.